Moderna Investing $500 M in New mRNA Vaccine Mfg Facility
Moderna has announced plans to build a new $500-million mRNA vaccine production facility in Africa for its COVID-19 vaccine and its other vaccine candidates with the goal of producing up to 500 million doses of vaccines each year at a 50-µg dose level.
The new facility will include drug-substance manufacturing with the opportunity for fill-finish and packaging capabilities at the site. Moderna says it expects to begin a process for country and site selection soon (as reported on October 7, 2021).
“While we are still working to increase capacity in our current network to deliver vaccines for the ongoing pandemic in 2022, we believe it is important to invest in the future,” said Moderna’s CEO, Stephane Bancel, in an October 7, 2021 statement. “We expect to manufacture our COVID-19 vaccine as well as additional products within our mRNA vaccine portfolio at this facility.”
To date (as reported on October 7, 2021), Moderna and its partners have ramped up capacity globally and have supplied more than 500 million doses of Moderna’s COVID-19 vaccine. Moderna’s pipeline includes 20 vaccine candidates against respiratory viruses, latent viruses and other disease targets.